دورية أكاديمية
Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
| العنوان: | Pasireotide: potential treatment option for McCune-Albright-associated acromegaly. |
|---|---|
| المؤلفون: | Ilie MD; Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, 69008 Lyon, France.; Endocrinology Department, 'C.I. Parhon' National Institute of Endocrinology, 011863, Bucharest, Romania., Raverot G; Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, 69008 Lyon, France.; Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, 'Groupement Hospitalier Est' Hospices Civils de Lyon, 69500 Bron, France., Brac de la Perrière A; Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, 'Groupement Hospitalier Est' Hospices Civils de Lyon, 69500 Bron, France. |
| المصدر: | European journal of endocrinology [Eur J Endocrinol] 2024 Jan 03; Vol. 190 (1), pp. K17-K20. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9423848 Publication Model: Print Cited Medium: Internet ISSN: 1479-683X (Electronic) Linking ISSN: 08044643 NLM ISO Abbreviation: Eur J Endocrinol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Oxford : Oxford University Press Original Publication: Oslo, Norway : Scandinavian University Press, c1994- |
| مواضيع طبية MeSH: | Acromegaly*/drug therapy , Human Growth Hormone*/therapeutic use, Humans ; Insulin-Like Growth Factor I/therapeutic use ; Somatostatin ; Glucose ; Treatment Outcome ; Octreotide/therapeutic use |
| مستخلص: | Only 30% of patients with McCune-Albright syndrome (MAS)-associated acromegaly achieve biochemical control under first-generation somatostatin receptor ligands (fg-SRLs), while pegvisomant fails to normalize insulin-like growth factor 1 (IGF-I) in >20% of cases. Here, we report all the patients with MAS-associated acromegaly treated with pasireotide long-acting release (LAR) in our center. Pasireotide LAR 20 mg/month resulted in rapid and long-term IGF-I normalization in patients #1 and #3. Patient #3 was resistant to fg-SRLs, while patient #1 was also controlled on fg-SRLs. In patient #2, resistant to fg-SRLs and uncontrolled on pegvisomant 40 mg/day combined with cabergoline 0.5 mg/day, pegvisomant was replaced with pasireotide LAR 40 mg/month, resulting in the near normalization of IGF-I levels. All 3 patients developed intermittent impaired fasting glucose, without the need for glucose-lowering drugs. Thus, pasireotide LAR is clearly useful as third-line therapy, and potentially even as second-line therapy, in MAS-associated acromegaly. Competing Interests: Conflict of interest: M.-D.I. and A.B.d.l.P. have no conflict of interest. G.R. has received consulting/speaker fees and/or he has been invited to conferences and/or he has participated in boards and/or clinical trials for Novartis, Pfizer, Ipsen, Recordati Rare Diseases, Amolyt, Crinetic, Novo Nordisk, and Chiasma. All the fees and honoraria are paid to his institution. G.R. is also on the editorial board of EJE. He was not involved in the review or editorial process for this paper, on which he is listed as author. (© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| فهرسة مساهمة: | Keywords: McCune–Albright syndrome; acrogigantism; acromegaly; pasireotide LAR |
| المشرفين على المادة: | 98H1T17066 (pasireotide) 67763-96-6 (Insulin-Like Growth Factor I) 51110-01-1 (Somatostatin) 12629-01-5 (Human Growth Hormone) IY9XDZ35W2 (Glucose) RWM8CCW8GP (Octreotide) |
| تواريخ الأحداث: | Date Created: 20231221 Date Completed: 20240112 Latest Revision: 20240125 |
| رمز التحديث: | 20240126 |
| DOI: | 10.1093/ejendo/lvad173 |
| PMID: | 38128124 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1479-683X |
|---|---|
| DOI: | 10.1093/ejendo/lvad173 |